{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"1.600","floor":"1.330"},"ipodate":{"start":"2010-11-12 00:00:00","end":"2010-11-17 00:00:00"},"minimumcapital":"6464.51","subscribed":"457.00","marketcap":"9.96億","H_marketcap":"--","pe":"18.56","codesrate":"20.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01110/LTN20101112044_C.pdf","ipopricing":"1.600","resultdate":"2010-11-24 00:00:00","enddate":"2010-11-17 00:00:00","listeddate":"2010-11-25 00:00:00","issuenumber":"15000.00萬","issuenumberhK":"7500.00萬","issuenumberother":"7500.00萬","grayprice":"--","sponsors":"國泰君安融資有限公司","raisemoney":"21670.00萬","use":"1、約60%或130.02百萬港元，將用作收購最多三項分銷業務；\n2、約20%或43.34百萬港元，將用作通過于深圳建立其自有配備標準GSP資格的配送中心第一階段以提升其向客戶運送貨物的服務；\n3、約10%或21.67百萬港元，將用作增加約3,000產品專柜；\n4、約10%或21.67百萬港元，將用作本集團的額外一般營運資金。","shares":4000,"leadagent":"國泰君安證券(香港)有限公司","bookrunners":"國泰君安證券(香港)有限公司","coordinator":"國泰君安證券(香港)有限公司","firstDayOpen":"2.01","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"國泰君安證券(香港)有限公司","code":"E01110","name":"金活醫藥集團","fullname":"金活醫藥集團有限公司"},"institutioninfo":{"principaloffice":"中國廣東省深圳市南山區大新路198號馬家龍創新大廈A座8-9樓","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"趙利生","secretary":"陳漢云","telephone":"(0755) 8229 2888","substantialshareholders":"趙利生及家族成員(64.59%),Sinopharm Healthcare Fund L.P.(9.99%)","principalactivities":"在中國分銷品牌進口藥品及保健產品。","website":"http://www.kingworld.com.cn"},"managerinfo":[],"investorinfo":[],"TotalShareholdingPercentage":0},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":514}